tetano
Editor, Senior Moderator
Immun Inflamm Dis
. 2024 Jul;12(7):e1353.
doi: 10.1002/iid3.1353. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization
Veronica A de Lima[SUP] 1 [/SUP], João P S Nunes[SUP] 1 [/SUP], Daniela S Rosa[SUP] 1 [/SUP], Rodrigo Ferreira[SUP] 2 [/SUP], Maria L V Oliva[SUP] 2 [/SUP], Robert Andreata-Santos[SUP] 1 [/SUP], Marcia Duarte-Barbosa[SUP] 1 [/SUP], Luiz M R Janini[SUP] 1 [/SUP], Juliana T Maricato[SUP] 1 [/SUP], Milena A Akamatsu[SUP] 3 [/SUP], Paulo L Ho[SUP] 3 [/SUP], Sergio Schenkman[SUP] 1 [/SUP]
Affiliations
Background: SARS-CoV2 virus, responsible for the COVID-19 pandemic, has four structural proteins and 16 nonstructural proteins. S-protein is one of the structural proteins exposed on the virus surface and is the main target for producing neutralizing antibodies and vaccines. The S-protein forms a trimer that can bind the angiotensin-converting enzyme 2 (ACE2) through its receptor binding domain (RBD) for cell entry.
Aims: The goal of this study was to express in HEK293 cells a new RBD recombinant protein in a constitutive and stable manner in order to use it as an alternative immunogen and diagnostic tool for COVID-19.
Materials & methods: The protein was designed to contain an immunoglobulin signal sequence, an explanded C-terminal section of the RBD, a region responsible for the bacteriophage T4 trimerization inducer, and six histidines in the pCDNA-3.1 plasmid. Following transformation, the cells were selected with geneticin-G418 and purified from serum-fre culture supernatants using Ni2+-agarand size exclusion chromatography. The protein was structurally identified by cross-linking and circular dichroism experiments, and utilized to immunize mice in conjuction with AS03 or alum adjuvants. The mice sera were examined for antibody recognition, receptor-binding inhibition, and virus neutralization, while spleens were evaluated for γ-interferon production in the presence of RBD.
Results: The protein released in the culture supernatant of cells, and exhibited a molecular mass of 135 kDa with a secondary structure like the monomeric and trimeric RBD. After purification, it formed a multimeric structure comprising trimers and hexamers, which were able to bind the ACE2 receptor. It generated high antibody titers in mice when combined with AS03 adjuvant (up to 1:50,000). The sera were capable of inhibiting binding of biotin-labeled ACE2 to the virus S1 subunit and could neutralize the entry of the Wuhan virus strain into cells at dilutions up to 1:2000. It produced specific IFN-γ producing cells in immunized mouse splenocytes.
Discussion: Our data describe a new RBD containing protein, forming trimers and hexamers, which are able to induce a protective humoral and cellular response against SARS-CoV2.
Conclusion: These results add a new arsenal to combat COVID-19, as an alternative immunogen or antigen for diagnosis.
Keywords: COVID ‐19; SARS‐CoV‐2; neutralizing antibody; protein S; receptor‐binding domain.
. 2024 Jul;12(7):e1353.
doi: 10.1002/iid3.1353. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization
Veronica A de Lima[SUP] 1 [/SUP], João P S Nunes[SUP] 1 [/SUP], Daniela S Rosa[SUP] 1 [/SUP], Rodrigo Ferreira[SUP] 2 [/SUP], Maria L V Oliva[SUP] 2 [/SUP], Robert Andreata-Santos[SUP] 1 [/SUP], Marcia Duarte-Barbosa[SUP] 1 [/SUP], Luiz M R Janini[SUP] 1 [/SUP], Juliana T Maricato[SUP] 1 [/SUP], Milena A Akamatsu[SUP] 3 [/SUP], Paulo L Ho[SUP] 3 [/SUP], Sergio Schenkman[SUP] 1 [/SUP]
Affiliations
- PMID: 39056544
- PMCID: PMC11273545
- DOI: 10.1002/iid3.1353
Background: SARS-CoV2 virus, responsible for the COVID-19 pandemic, has four structural proteins and 16 nonstructural proteins. S-protein is one of the structural proteins exposed on the virus surface and is the main target for producing neutralizing antibodies and vaccines. The S-protein forms a trimer that can bind the angiotensin-converting enzyme 2 (ACE2) through its receptor binding domain (RBD) for cell entry.
Aims: The goal of this study was to express in HEK293 cells a new RBD recombinant protein in a constitutive and stable manner in order to use it as an alternative immunogen and diagnostic tool for COVID-19.
Materials & methods: The protein was designed to contain an immunoglobulin signal sequence, an explanded C-terminal section of the RBD, a region responsible for the bacteriophage T4 trimerization inducer, and six histidines in the pCDNA-3.1 plasmid. Following transformation, the cells were selected with geneticin-G418 and purified from serum-fre culture supernatants using Ni2+-agarand size exclusion chromatography. The protein was structurally identified by cross-linking and circular dichroism experiments, and utilized to immunize mice in conjuction with AS03 or alum adjuvants. The mice sera were examined for antibody recognition, receptor-binding inhibition, and virus neutralization, while spleens were evaluated for γ-interferon production in the presence of RBD.
Results: The protein released in the culture supernatant of cells, and exhibited a molecular mass of 135 kDa with a secondary structure like the monomeric and trimeric RBD. After purification, it formed a multimeric structure comprising trimers and hexamers, which were able to bind the ACE2 receptor. It generated high antibody titers in mice when combined with AS03 adjuvant (up to 1:50,000). The sera were capable of inhibiting binding of biotin-labeled ACE2 to the virus S1 subunit and could neutralize the entry of the Wuhan virus strain into cells at dilutions up to 1:2000. It produced specific IFN-γ producing cells in immunized mouse splenocytes.
Discussion: Our data describe a new RBD containing protein, forming trimers and hexamers, which are able to induce a protective humoral and cellular response against SARS-CoV2.
Conclusion: These results add a new arsenal to combat COVID-19, as an alternative immunogen or antigen for diagnosis.
Keywords: COVID ‐19; SARS‐CoV‐2; neutralizing antibody; protein S; receptor‐binding domain.